U.S. markets closed
  • S&P Futures

    4,130.75
    -2.00 (-0.05%)
     
  • Dow Futures

    33,528.00
    -42.00 (-0.13%)
     
  • Nasdaq Futures

    13,967.50
    -8.25 (-0.06%)
     
  • Russell 2000 Futures

    2,222.90
    -2.00 (-0.09%)
     
  • Crude Oil

    60.50
    +0.32 (+0.53%)
     
  • Gold

    1,746.30
    -1.30 (-0.07%)
     
  • Silver

    25.38
    -0.05 (-0.18%)
     
  • EUR/USD

    1.1960
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    1.6230
    -0.0520 (-3.10%)
     
  • Vix

    16.65
    -0.26 (-1.54%)
     
  • GBP/USD

    1.3760
    +0.0008 (+0.06%)
     
  • USD/JPY

    108.8600
    -0.1880 (-0.17%)
     
  • BTC-USD

    63,352.86
    +3,348.19 (+5.58%)
     
  • CMC Crypto 200

    1,358.10
    +64.10 (+4.95%)
     
  • FTSE 100

    6,890.49
    +1.37 (+0.02%)
     
  • Nikkei 225

    29,635.86
    -115.75 (-0.39%)
     

Autolus Therapeutics Raises $100M Via Equity

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Autolus Therapeutics PLC (NASDAQ: AUTLprices an underwritten public offering in the U.S. of 14.3 million American Depositary Shares (ADS) representing 14.3 million ordinary shares at $7 per ADS, for total gross proceeds of approximately $100 million. Underwriters have an option to purchase up to an additional 2.1 million ADSs.

  • The offering is expected to close on February 12.

  • J.P. Morgan and Wells Fargo Securities are acting as joint book-runners for the offering.

  • Autolus did not mention the use for the proceeds raised. Still, last month, it prioritized the development of AUTO1 and thus planned to cut headcount by approximately 20% resulting in annualized savings of $15 million. AUTO1 is under development for adult acute lymphoblastic leukemia, with full data from the AUTO1-AL1 study expected in 2022.

  • Autolus plans to seek a partner for the AUTO3 program, its CAR T product candidate for relapsed/refractory diffuse large B cell lymphoma, ahead of progressing into the next phase of development.

  • Price Action: AUTL slid 2% at $7.35 during the premarket trading on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.